Monday, September 14, 2026

Trump’s Second Term Tests Seoul—Then Resets It: How U.S.–Korea Ties Swung From Crisis to Deal-Making

U.S.-South Korea relations fluctuated under Trump, but Lee Jae Myung's administration restored communication and secured key agreements.

Fortified Borders Can’t Stop North Korean Defectors: Third Escape in Months

Despite North Korea's fortified borders, three defectors have crossed into South Korea since August, highlighting ongoing challenges.

North Korea Expands Cyberattacks, Suspected of Breaching South Korea’s Government Document System

North Korea is suspected of hacking South Korea's document system, leading to data breaches and concerns over cybersecurity vulnerabilities.

Tag: GLP-1

North KoreaKoreaKimMilitaryAISouth Koreamarketrelationsdevelopment

Korean Obesity Drug Set to Launch Next Month as Hanmi’s Efe Targets Market

Hanmi Pharmaceutical plans to launch its domestically developed GLP-1 obesity drug Efe as early as next month, with Korean clinical data, safety and domestic production as key selling points.

Unlocking the Future: How Genomic Testing Enhances GLP-1 Obesity Treatment for Asian Patients

NGeneBio is developing tests to identify which patients benefit from GLP-1 weight loss drugs like Wegovy and Mounjaro, assessing side effects.

JW Pharmaceutical Files for South Korea Phase 3 Trial of Once-Every-Two-Weeks Obesity Drug

JW Pharmaceutical is seeking to advance Bofanglutide into a South Korean Phase 3 trial, aiming to halve the dosing frequency of GLP-1 obesity treatments from once weekly to once every two weeks.

‘Dream Weight-Loss Drug’ Wegovy May Also Protect Brain Health by Reducing Risk of Adult-Onset Seizures

Semaglutide may reduce adult-onset seizure risk by 56%, suggesting a link between metabolic treatment and brain health.

AstraZeneca’s Elecoglipron: Can This New Weight Loss Pill Compete with GLP-1 Giants?

AstraZeneca's new weight-loss pill, elecoglipron, shows promising results in trials, competing with existing obesity treatments.

Wegovy Breaks Records: 3 Million Prescriptions in Just 5 Months – What You Need to Know

Wegovy surpasses 3 million prescriptions in 5 months, marking a significant milestone in the U.S. obesity treatment market.

Wegovy, Mounjaro Boom Creates New Winners as Ursa, InBody Ride GLP-1 Ripple Effects

GLP-1 obesity drugs are boosting gallstone prevention therapies and body composition monitoring, creating new market opportunities.

Samsung Launches GLP-1 Muscle Loss Study With Galaxy Watch8 and Harvard-Linked Hospital

Samsung is researching muscle loss management for GLP-1 drug users, led by the Galaxy Watch 8.

Celltrion Moves CT-G32 Into Final Preclinical Stage as Global Obesity Trial Preparation Accelerates

Celltrion advances CT-G32, a next-gen obesity treatment, targeting multiple pathways to enhance weight loss while preserving muscle mass.

MetaVia to Present DA-1726 Phase 1 Obesity Trial Data at EASL Congress 2026

Dong-A ST's Meta via will present DA-1726, a dual-action obesity treatment, at the EASL Congress 2026, showcasing promising clinical trial results.

Novo Nordisk’s Oral Wegovy Just Put Up a Number That Could Change the Obesity Drug Race

Novo Nordisk's oral obesity treatment, Wegovy, saw $400M in Q1 2026 sales, exceeding estimates and indicating strong market demand.

Unlocking Weight Loss: How GB102 Probiotics Enhance GLP-1 Obesity Drugs

GI Longevity's GB102 probiotic enhances weight loss with GLP-1 medications, reducing rebound gain and improving blood sugar control.

Metabia Begins Dosing First Patient in Phase 1 Part 3 Trial of Obesity Drug DA-1726

Metabia begins Phase 1 trial for DA-1726, a dual-action obesity treatment, aiming for safety and efficacy in weight loss by 2026.

Eli Lilly’s New Weight Loss Pill Foundayo: A Game Changer in the GLP-1 Market?

The FDA has approved Eli Lilly's oral obesity drug Foundayo, enhancing competition in the weight loss market with flexible dosing.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.